Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) has earned an average recommendation of “Moderate Buy” from the nine research firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $18.57.
A number of research firms have weighed in on DSGN. Wall Street Zen downgraded Design Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Design Therapeutics in a research note on Thursday, October 15th. Wells Fargo & Company started coverage on Design Therapeutics in a report on Friday, October 2nd. They issued an “overweight” rating and a $26.00 price objective for the company. Finally, Royal Bank Of Canada lowered their price objective on Design Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research report on Thursday, November 5th.
Read Our Latest Stock Analysis on DSGN
Institutional Inflows and Outflows
Design Therapeutics Trading Down 3.3%
Shares of DSGN opened at $9.01 on Thursday. The firm’s 50-day moving average price is $11.14 and its 200-day moving average price is $12.14. The firm has a market capitalization of $577.00 million, a price-to-earnings ratio of -7.51 and a beta of 1.73. Design Therapeutics has a 1-year low of $7.82 and a 1-year high of $17.25.
Design Therapeutics (NASDAQ:DSGN – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.02. On average, research analysts forecast that Design Therapeutics will post -1.41 EPS for the current fiscal year.
Design Therapeutics Company Profile
Design Therapeutics is a clinical-stage biotechnology company developing medicines for inherited diseases. Its research focuses on conditions associated with genetic repeat expansions, in which repeated DNA sequences can disrupt the normal activity of a gene. The company’s GeneTAC platform is designed to create small molecules that interact with these expanded genetic sequences and help restore gene expression. Design Therapeutics aims to use this approach to address the underlying causes of disease rather than only manage symptoms.
Read More
- Five stocks we like better than Design Therapeutics
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Design Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Design Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
